ASMB Stock Forecast: Assembly Biosciences, Inc. Price Predictions for 2026-2027
The 5 Wall Street analysts covering Assembly Biosciences, Inc. hold a median 12-month price target of $50 — +125.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 79 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Assembly Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (96): The business earns solid, repeatable profits on what it owns.
Accruals (8): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ASMB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ASMB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +125.3% from it.
Of the 20 most recent actions, 2 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Nov 2026 | UBS | Maintains | Buy | $52 → $48 |
| 1 Sept 2026 | Mizuho | Maintains | Outperform | $53 → $45 |
| 1 Sept 2026 | UBS | Initiates | Buy | $52 |
| 18 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $50 |
| 15 June 2026 | Mizuho | Maintains | Outperform | $40 → $45 |
| 28 May 2026 | Guggenheim | Reiterates | Buy | — |
| 4 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Apr 2026 | Guggenheim | Maintains | Buy | — |
| 26 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Nov 2025 | Mizuho | Maintains | Outperform | — |
| 14 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Sept 2025 | JMP Securities | Initiates | Market Outperform | — |
| 8 Sept 2025 | Guggenheim | Maintains | Buy | — |
| 18 Aug 2025 | HC Wainwright & Co. | Assumes | Buy | $50 |
| 25 Mar 2025 | Guggenheim | Initiates | Buy | — |
| 24 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 27 Dec 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 24 Sept 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 20 Sept 2024 | Jefferies | Upgrade | Buy | $2.00 → $35 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ASMB.
This page is one stock. Monday covers all of them.
ASMB appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ASMB vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Assembly Biosciences, Inc. returned −39.6% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ASMB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 29.6×
- Price / sales
- 6.8×
- Price / book
- 1.5×
- EV / EBITDA
- —
Cheaper than 29% of US stocks
Cheaper than 16% of US stocks
Cheaper than 54% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −31.8%
- Net margin
- —
Higher than 20% of US stocks
- Return on equity
- −4.6%
- Return on assets
- −4.7%
- Dividend yield
- —
Higher than 40% of US stocks
Higher than 33% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Assembly Biosciences, Inc. has a market value of $454.4M and an enterprise value of $142.3M.
Revenue in the twelve months to 30 June 2026: $74.8M. The latest quarter grew 38.9% year on year.
Net income over the same four quarters: −$42K, a −0.1% net margin.
Free cash flow in the twelve months to 30 June 2026: −$38.6M.
Trailing P/E: 29.6×.
Assembly Biosciences, Inc. employs 73 people — $1.0M of revenue per employee.
Data provided by Twelve Data
ASMB and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ASMB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Assembly Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ASMB
What is the ASMB stock price forecast for 2026-2027?
The 5 Wall Street analysts covering Assembly Biosciences, Inc. have a median 12-month price target of $50, with estimates ranging from $43 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ASMB stock a buy right now?
Of the 5 analysts covering Assembly Biosciences, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Assembly Biosciences, Inc. 79 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ASMB?
As at 21 Nov 2026, Assembly Biosciences, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).
Will ASMB stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +125.3% from the last close, and Ticker Nerd's factor model ranks Assembly Biosciences, Inc. 79 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ASMB stock forecast for 2030?
No analyst covering Assembly Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ASMB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $62 over the next 12 months.
How has ASMB stock performed over the past year?
Assembly Biosciences, Inc. returned -39.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Assembly Biosciences, Inc. do?
Assembly Biosciences Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapeutics for serious viral and liver diseases. Its current pipeline includes investigational treatments for recurrent genital herpes, hepatitis B virus, hepatitis D virus, and other infectious conditions, with programs designed to target key stages of viral replication and disease progression.
About Assembly Biosciences, Inc.
Assembly Biosciences Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapeutics for serious viral and liver diseases. Its current pipeline includes investigational treatments for recurrent genital herpes, hepatitis B virus, hepatitis D virus, and other infectious conditions, with programs designed to target key stages of viral replication and disease progression. The company also advances research in related areas such as cholestatic liver disease and microbiome-linked disorders through orally delivered therapeutic candidates. Assembly Biosciences Inc. works across discovery, preclinical, and clinical development, positioning itself within the infectious disease and liver disease segments of the biotechnology market. Headquartered in South San Francisco, California, the company concentrates on creating novel treatment approaches intended to address unmet medical needs in virology and liver health.
CEO Mr. Jason A. Okazaki J.D. · 73 employees · United States · https://www.assemblybio.com